<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Biotechnology</title>
	<atom:link href="http://www.stockbloghub.com/category/biotechnology/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(QGEN) Qiagen Beats Earnings Forecasts &#8211; Reiterates Outllook</title>
		<link>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817</link>
		<comments>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99817</guid>
		<description><![CDATA[Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating the Zacks Consensus Estimate of 19 cents as well as the year-ago quarter earnings by a couple of cents. The improvement in the bottom line was driven by double–digit sales growth and efficient cost management. In the fourth quarter, all the operational regions of the company delivered double-digit growth at CER. Region wise, Americas (47% of revenues) witnessed a 15% increase in sales at CER, driven by strong contributions from the US, Brazil and Canada. However, revenues from Europe- Middle East-Africa (34% of sales) and Asia-Pacific /Japan (18% of sales) increased 12% and 18% at CER, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Still Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209</link>
		<comments>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209#comments</comments>
		<pubDate>Mon, 02 Apr 2012 17:37:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97209</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta in March 2011 for treating patients suffering from systemic lupus erythematosus (SLE) was a huge positive for Human Genome. The subsequent launch of the drug in Canada and several European nations, including Germany, Spain, Austria, Denmark, Finland, Hungary, Norway and Sweden is also encouraging. Benlysta, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Sales of the drug are growing, albeit slowly. Net sales of Benlysta improved 36.7% sequentially to $25.7 million in the final quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon&#8217;s Provenge Showing Bleak Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847</link>
		<comments>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847#comments</comments>
		<pubDate>Mon, 05 Mar 2012 15:19:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=93847</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate loss of 31 cents and year-ago loss of 60 cents per share. Full-year loss of $1.68 per share (excluding special items but including stock-based compensation expense) were narrower than the Zacks Consensus Estimate of a loss of $2.83 and the year-ago loss of $3.07 per share. Total revenue in the reported quarter climbed to $202.1 million from $25.0 million in the comparable quarter of 2010. We note, however, that revenue in the reported quarter included one time royalty revenue of $125 million related to sale of its royalty interest in Merck, Inc.’s (MRK) hepatitis C product Victrelis. Excluding this one-time revenue, Dendreon ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806</link>
		<comments>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806#comments</comments>
		<pubDate>Sun, 19 Feb 2012 03:43:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91806</guid>
		<description><![CDATA[We have maintained a Neutral rating on Gilead Sciences, Inc. (GILD) following appraisal of fourth quarter and full year 2011 results. Gilead’s adjusted earnings per share of 92 cents (including stock option expense) for the fourth quarter of 2011 missed the Zacks Consensus Estimate by 8 cents, as higher revenues were offset by increased research and development (R&#38;D) expenses. However, earnings were 2 cents above the year-earlier figure of 90 cents. Fourth quarter revenues were up 10% from the prior-year quarter to $2.2 billion, spurred by higher product sales. Total revenue also edged past the Zacks Consensus Estimate of $2.19 billion. Other than the fourth quarter miss, 2011 was an eventful year for Gilead on all fronts, namely commercial, regulatory and financial. Gilead’s strategy of creating fixed-dose combinations of existing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) Update on ViroPharma Industrial Facility</title>
		<link>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534</link>
		<comments>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:55:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[PAS]]></category>
		<category><![CDATA[PepsiAmericas Inc.]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91534</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Cinryze’s industrial scale manufacturing facility. The regulatory body made three comments related to a portion of the cleaning validation for industrial scale manufacturing, of which only one requires additional unplanned activity. ViroPharma does not expect this activity to take much time to complete. The FDA also said that it has not finished reviewing the company’s January 2012 updated responses to observations specific to the September 2011 inspection of the Amsterdam facility. We note that ViroPharma undertook an expansion of the production capacity for Cinryze in 2009. In early 2010, the company submitted the Cinryze industrial scale manufacturing Prior Approval Supplement (PAS) to the FDA. In October 2010, the regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Analyst Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609</link>
		<comments>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609#comments</comments>
		<pubDate>Sat, 21 Jan 2012 20:38:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90609</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continues to see an increase in patients despite carrying a “black box” warning for the risk of progressive multifocal leukoencephalopathy (PML) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri’s launch in new markets like India, Brazil, Argentina, the Middle East and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ILMN) Two Major Biotech Trends In 2012</title>
		<link>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438</link>
		<comments>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438#comments</comments>
		<pubDate>Thu, 19 Jan 2012 23:34:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90438</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate a few tons of filets and guzzled thousands of gallons of Starbucks coffee. What makes the conference such a big deal is that it’s the largest and most important investor event of the year in the healthcare sector. There are other healthcare conferences put on by investment banks, but nothing comes close to the quality and number of companies and attendees at JPM. There were two important takeaways that emerged from the conference – themes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404</link>
		<comments>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:45:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90404</guid>
		<description><![CDATA[We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up 36%). Preliminary adjusted revenues in the final quarter of 2011 came in at $1.28 billion, 22% above the year-ago figure. For 2011, sales came in at $4.8 billion, up 34%. The company also gave a bright outlook for 2012 with adjusted earnings expected to improve by 25%. We believe that Celgene, driven by its oncology portfolio and robust pipeline, should easily achieve the 2012 guidance. We believe that the current price represents an attractive entry point for long-term investors. Based on 2012 P/E estimates, the stock is trading at 17.4x earnings, compared to the industry average of 28.1. Our target ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma  Drug Earns Priority Review</title>
		<link>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265</link>
		<comments>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:37:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90265</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company expects Health Canada to complete its review of Cinryze in the second half of 2012. We note that Cinryze is currently marketed in the US for the prevention of angioedema attacks in adolescent and adult patients with HAE. In the European Union (EU), the same drug is marketed for the treatment of prevention, pre-procedure prevention, and treatment of attacks of HAE in adolescents and adult patients. We view this development as a positive for ViroPharma, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot</title>
		<link>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940</link>
		<comments>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940#comments</comments>
		<pubDate>Fri, 13 Jan 2012 20:59:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[ITMN]]></category>
		<category><![CDATA[NPP]]></category>
		<category><![CDATA[Nuveen Performance Plus Municipal Fund Inc]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89940</guid>
		<description><![CDATA[InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The drug has been launched first in Germany in September 2011. InterMune also announced updated data from the drug’s RECAP study. Preliminary Esbriet Update InterMune reported Esbriet revenue of $2.8 million since launch in September 2011, of which $2.7 million was generated in Germany. Management announced that 1,022 new patients started Esbriet therapy across EU at the end of 2011. Of these, 612 patients have been given Esbriet in Germany and 410 patients have enrolled in the named patient program (NPP) outside Germany. Under the NPP program qualified physicians can make Esbriet available to IPF patients in EU ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam States Preclinical Data</title>
		<link>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523</link>
		<comments>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523#comments</comments>
		<pubDate>Tue, 03 Jan 2012 19:15:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89523</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington&#8217;s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington&#8217;s disease. Further, ALN-HTT was well tolerated in these studies. ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food &#38; Drug Administration (FDA) will allow the candidate to enter early stage clinical trials. Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596</link>
		<comments>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596#comments</comments>
		<pubDate>Thu, 15 Dec 2011 10:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88596</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. The EU approval does not surprise us since in September this year Dificlir received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. Dificlir is already marketed as Dificid in the US for CDAD in partnership with Cubist Pharmaceuticals, Inc. (CBST). The European regulatory body’s decision was based on data from two late stage studies which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Moved Down to Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901</link>
		<comments>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87901</guid>
		<description><![CDATA[We recently downgraded our rating on Optimer Pharmaceuticals Inc. (OPTR) to Neutral from Outperform as we await more visibility on how the commercial launch of its sole marketed antibiotic Dificid (fidaxomicin) takes shape. Optimer launched Dificid in July 2011 in the US for the treatment of clostridium difficile-associated diarrhea (CDAD). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities.  Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid scores better than currently available treatment options on many parameters. Dificid has been shown to be non-inferior to ViroPharma’s (VPHM) Vancocin (the only other FDA approved antibiotic for the treatment of clostridium difficile infection) in late stage studies in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928</link>
		<comments>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:17:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87928</guid>
		<description><![CDATA[Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA), a rare genetic enzyme deficiency disorder. The company intends to evaluate the safety and tolerability of the drug dosed at 2.0 mg/kg/week over a period of one year. The study will evaluate 10 to 15 children below 5 years of age. The open-label, multinational study will also evaluate the levels of urinary keratan sulfate (KS) and growth velocity. Apart from the mid-stage study in children, GALNS is also being evaluated in a randomized, double-blind, placebo-controlled late-stage study (n~160) in the MPS IVA indication. BioMarin is enrolling patients in a late stage study with primary endpoint of six-minute walk distance. Enrollment is underway in the 24-week study. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278</link>
		<comments>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278#comments</comments>
		<pubDate>Fri, 09 Dec 2011 17:40:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88278</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also adjusting for the change in fair value of warrants). Lower-than-expected revenues led to the wider loss in the quarter. Revenues at Micromet were down almost 33% from the prior-year period to $4.5 million in the third quarter of 2011 due to lower collaboration revenue. Moreover, revenues in the year-ago quarter were boosted by the presence of a milestone payment from AstraZeneca (AZN). Revenues were also much below the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead&#8217;s Eviplera Drug is Cleared by European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725</link>
		<comments>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:44:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87725</guid>
		<description><![CDATA[Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed HIV drug Truvada (a fixed-dose, once-daily tablet containing Gilead&#8217;s Viread and Emtriva) and Johnson and Johnson’s (JNJ) new HIV drug Edurant. The STR is already marketed as Complera in the US. The EMA however limited the use of Eviplera only in patients with low viral load (below 100,000 HIV RNA copies/mL). Complera/ Eviplera is the second STR approved in the EU for the treatment of HIV, the first being Atripla, which is marketed by Gilead and Bristol Myers Squibb (BMY). Gilead has a license and collaboration agreement with Tibotec Pharmaceuticals ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ITMN) InterMune Reports Quarterly Loss Smaller Than Estimates</title>
		<link>http://www.stockbloghub.com/2011/11/10/itmn-intermune-reports-quarterly-loss-smaller-than-estimates/86642</link>
		<comments>http://www.stockbloghub.com/2011/11/10/itmn-intermune-reports-quarterly-loss-smaller-than-estimates/86642#comments</comments>
		<pubDate>Thu, 10 Nov 2011 17:45:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[ITMN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86642</guid>
		<description><![CDATA[InterMune, Inc. (ITMN) posted third-quarter adjusted loss per share of 63 cents, wider than the year-ago loss per share of 44 cents due to higher operating expenses. The loss was, however, narrower than the Zacks Consensus Estimate of a loss per share of 73 cents resulting from lower-than-expected R&#38;D expenses. InterMune reported revenues of $5.2 million in the third quarter, below the year-ago revenue of $5.7 million. Slightly higher revenues of InterMune’s marketed drug Actimmune was offset by decreased collaboration revenue from the termination of research agreement with Roche Holdings Ltd. (RHHBY) effective from June 30, 2011. Revenue included $0.1 million earned from the sales of InterMune’s potential blockbuster drug Esbriet which was launched in Germany in September this year. Esbriet is approved for the treatment of idiopathic pulmonary fibrosis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/10/itmn-intermune-reports-quarterly-loss-smaller-than-estimates/86642/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/07/mdvn-medivation-incorporated-bull-of-the-day/86618</link>
		<comments>http://www.stockbloghub.com/2011/11/07/mdvn-medivation-incorporated-bull-of-the-day/86618#comments</comments>
		<pubDate>Mon, 07 Nov 2011 15:14:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86618</guid>
		<description><![CDATA[Medivation, Inc. (MDVN) shares received a major boost recently with the company and its partner, Astellas, reporting impressive data on MDV3100 from a pre-specified interim analysis of a phase III study, AFFIRM. The Independent Data Monitoring Committee (IDMC) recommended that MDV3100&#8242;s risk-to-benefit ratio was favorable enough to stop the study. Medivation and Astellas intend to conduct a pre-NDA meeting with the FDA in early 2012. We believe the companies will file for regulatory approval of MDV3100 soon thereafter and expect MDV3100 to hit the market in 2013. Based on the data that we have seen so far, we believe MDV3100 has blockbuster potential and will be a game-changer for Medivation. We are upgrading Medivation to Outperform based on the improved prospects of the company. MEDIVATION INC (MDVN): Free Stock Analysis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/07/mdvn-medivation-incorporated-bull-of-the-day/86618/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Loss Narrows</title>
		<link>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549</link>
		<comments>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549#comments</comments>
		<pubDate>Sun, 06 Nov 2011 19:55:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86549</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance of its prostate cancer vaccine Provenge in the quarter. Loss was, however, much wider than the year-ago loss of 54 cents per share. Quarterly Details Total revenue in the reported quarter climbed to $64.3 million (including rebates and charge-backs) from $20.2 million in the comparable quarter of 2010. The jump was attributable to the higher Provenge revenue in the current quarter versus low Provenge sales in the third quarter of 2010 as it was only the second quarter of its launch. Revenues were also above the Zacks Consensus Estimate of $63 million. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Going Strong</title>
		<link>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191</link>
		<comments>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86191</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting an increase of 8.3%. Higher revenues and lower share count helped boost earnings. Revenues Higher sales from Cinryze helped improve quarterly revenues to $143.0 million, from $117.8 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 33.2% to $65.4 million during the reported quarter, and Vancocin sales came in at $76.6 million, reflecting an increase of 13.3%. While the increase in Cinryze sales was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Third Quarter Loss Deteriorates</title>
		<link>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313</link>
		<comments>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:01:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[FF]]></category>
		<category><![CDATA[First Opportunity Fund Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICS]]></category>
		<category><![CDATA[Morgan Stanley Insured California Municipal Securi]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86313</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research and development (R&#38;D) expenses. Revenue at Theravance though up 21.3% over the prior year to $6.4 million was below the Zacks Consensus Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.8 million on Vibativ sales from Astellas Pharma on net sales of $4.5 million. Vibativ, Theravance’s only commercialized drug, is an injectable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/01/hgsi-human-genome-sciences-bear-of-the-day/86260</link>
		<comments>http://www.stockbloghub.com/2011/11/01/hgsi-human-genome-sciences-bear-of-the-day/86260#comments</comments>
		<pubDate>Tue, 01 Nov 2011 20:44:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86260</guid>
		<description><![CDATA[We are downgrading Human Genome Sciences Inc. (HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. The company suffered a wider-than-expected loss due to lower revenues. The most alarming factor was the below-par showing of Human Genome&#8217;s recently launched lupus drug, Benlysta. Following the lackluster showing, we have increased our loss per share estimates for 2011 and 2012. Moreover, management has pushed back its aim of turning profitable by a year to 2014. In view of these headwinds, we see little reason for investors to hold on to the stock at current levels. Our target price is $10.00. HUMAN GENOME (HGSI): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/01/hgsi-human-genome-sciences-bear-of-the-day/86260/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/26/celg-celgene-corporation-bull-of-the-day/85898</link>
		<comments>http://www.stockbloghub.com/2011/10/26/celg-celgene-corporation-bull-of-the-day/85898#comments</comments>
		<pubDate>Wed, 26 Oct 2011 13:43:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85898</guid>
		<description><![CDATA[We are upgrading Celgene Corporation (CELG) to Outperform from Neutral following strong second quarter results delivered by the company and the decision of CHMP that the benefits associated with Revlimid outweigh the risks in multiple myeloma patients. Celgene performed impressively in the second quarter of 2011 and beat the Zacks Consensus Estimate both in terms of revenues and earnings. Following the strong showing, Celgene upped its guidance for 2011. The stock has reacted favorably to the recent positive developments. Celgene, driven by its oncology portfolio and robust pipeline, is expected to continue performing impressively. We believe that the current price represents an attractive entry point for long-term investors. Our target price is $80.00. CELGENE CORP (CELG): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/26/celg-celgene-corporation-bull-of-the-day/85898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Posts Lower Loss</title>
		<link>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689</link>
		<comments>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:38:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[iShares S&P Target Date 2010]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NICE Systems Limited]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TZD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85689</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third quarter revenues, which included a $15 million milestone payment, increased 12.1% to $175 million. Revenues exceeded the Zacks Consensus Estimate of $166 million. Quarterly Details Quarterly revenues consisted of $155.1 million in product sales (up 0.7%) and $19.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Collaborative revenues included a $15 million milestone payment from Lilly on the launch of Bydureon in the EU. Collaborative ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/13/ctic-cell-therapeutics-incorporated-bull-of-the-day/85021</link>
		<comments>http://www.stockbloghub.com/2011/10/13/ctic-cell-therapeutics-incorporated-bull-of-the-day/85021#comments</comments>
		<pubDate>Thu, 13 Oct 2011 16:31:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85021</guid>
		<description><![CDATA[In late September, Cell Therapeutics (CTIC) announced that a second independent radiologic review of data from the pivotal trial PIX301 of lead drug pixantrone for aggressive NHL confirmed the statistical significance of response and progression endpoints. With this positive development, we believe pixantrone is getting closer to approval. We are encouraged by the FDA&#8217;s decision to allow Cell Therapeutics to re-submit the NDA for pixantrone for review without the need for an additional trial. We are therefore upgrading our rating on the stock from Neutral to Outperform. Cell Therapeutics second most advanced pipeline candidate, Opaxio, is being studied as a potential maintenance therapy for women with advanced ovarian cancer who achieve complete remission following first-line therapy with paclitaxel and carboplatin. The phase III study, GOG0212, has already enrolled more than ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/13/ctic-cell-therapeutics-incorporated-bull-of-the-day/85021/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757#comments</comments>
		<pubDate>Thu, 06 Oct 2011 23:38:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84757</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to evaluate the safety and tolerability of the candidate in patients suffering from high low-density lipoprotein cholesterol (LDLc or “bad” cholesterol). Moreover, the clinical activity of ALN-PCS is also expected to be assessed through the study on the basis of measurements of plasma PCSK9 protein and serum LDLc. Results from the study, which is being conducted in the UK, are expected by year end. ALN-PCS is a part of Alnylam’s core product strategy &#8211; 5&#215;15 introduced ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Company News for October 6, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/10/06/acor-company-news-for-october-6-2011-corporate-summary/84712</link>
		<comments>http://www.stockbloghub.com/2011/10/06/acor-company-news-for-october-6-2011-corporate-summary/84712#comments</comments>
		<pubDate>Thu, 06 Oct 2011 17:43:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Acuity Brands Inc.]]></category>
		<category><![CDATA[AYI]]></category>
		<category><![CDATA[CBEY]]></category>
		<category><![CDATA[Cbeyond Inc]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[CTC Media Inc]]></category>
		<category><![CDATA[CTCM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MON]]></category>
		<category><![CDATA[Monsanto Company]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84712</guid>
		<description><![CDATA[•    Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25 billion from $1.95 billion •    Reacting to news that Microsoft (NASDAQ:MSFT) is considering a bid for Yahoo (NASDAQ:YHOO), shares of the company gained 3.30% to close at $25.89 •    Share prices of lightning manufacture Acuity Brands Inc. (NYSE:AYI) increased 11.67% to close at $37.73 after the company posted a profitable fourth quarter results •    Share prices Lufkin Industries Inc. (NASDAQ:LUFK) fell 8.79% during the early hours of the days trade after the company lowered its outlook for the third-quarter •    Analysts at Citigroup upgraded shares of Acorda Therapeutics (NASDAQ:ACOR) to &#8220;Buy&#8221; rating from &#8220;Hold&#8221; rating •    Analysts at Citi ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/acor-company-news-for-october-6-2011-corporate-summary/84712/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut</title>
		<link>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114</link>
		<comments>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114#comments</comments>
		<pubDate>Tue, 27 Sep 2011 20:45:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84114</guid>
		<description><![CDATA[Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second quarter, Enzon announced that it will no longer develop three messenger ribonucleic acid (mRNA) antagonists utilizing the LNA technology and returned the rights to Santaris. The mRNA antagonists, all of which were in phase I trials, were hypoxia-inducible factor-1 alpha (HIF-1 a) indicated for tumors and lymphoma, survivin indicated for cancer and pediatric patients with relapse acute lymphoblastic leukemia and androgen receptor (AR) for castration-resistant prostate cancer (CRPC). Earlier, in mid-May 2011, Enzon announced plans to halt the development of its lead pipeline candidate PEG-SN38 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960</link>
		<comments>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960#comments</comments>
		<pubDate>Sat, 24 Sep 2011 18:58:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83960</guid>
		<description><![CDATA[Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for the District of Massachusetts. The lawsuit claims that Amphastar Pharma&#8217;s generic Lovenox, which was approved by the US Food and Administration (FDA) on September 19, infringes two of Momenta&#8217;s US patents. Amphastar Pharma plans to launch generic Lovenox in the US in the fourth quarter of 2011. Lovenox is indicated for the prophylaxis and treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction. According to IMS Health, US sales of Lovenox and its generic equivalents amounted to about $2.6 billion for the twelve months ended ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRX) Medicis Pharmaceutical Sells LipoSonix Business</title>
		<link>http://www.stockbloghub.com/2011/09/20/mrx-medicis-pharmaceutical-sells-liposonix-business/83304</link>
		<comments>http://www.stockbloghub.com/2011/09/20/mrx-medicis-pharmaceutical-sells-liposonix-business/83304#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:26:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83304</guid>
		<description><![CDATA[Medicis Pharmaceutical Corp. (MRX) recently announced to have entered into a ‘Stock Purchase Agreement’ with Solta Medical, Inc. (SLTM), under which the latter will acquire all the outstanding shares of Medicis Technologies Corporation (formerly LipoSonix, Inc.), a subsidiary of Medicis Pharma. The deal is expected to close in the fourth quarter of 2011. According to the agreement, Solta will make a payment of $15 million to Medicis Pharma following the closure of the deal. Additionally, Solta will pay up to $20 million to Medicis Pharma on the achievement of certain regulatory milestones. Medicis Pharma is also entitled to receive payments based on the future performance of the LipoSonix technologies. Solta&#8217;s obligation to make these additional future payments expires after about 7 years. We note that the LipoSonix system is currently ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/mrx-medicis-pharmaceutical-sells-liposonix-business/83304/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma and Halozyme Therapeutics Begin Trial</title>
		<link>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259</link>
		<comments>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:40:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83259</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) and its partner Halozyme Therapeutics (HALO) recently announced the initiation of a mid-stage trial on its drug Cinryze. The phase II study is designed to evaluate the safety, and pharmacokinetics and pharmacodynamics of the subcutaneous formulation of Cinryze in combination with Halozyme&#8217;s Enhanze technology, in patients suffering from hereditary angioedema (HAE). Cinryze in the intravenous form is currently marketed worldwide as a treatment for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. The Enhanze technology is a proprietary drug-delivery platform, using Halozyme&#8217;s recombinant human hyaluronidase enzyme (rHuPH20). This proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. The initiation of the trial triggered a milestone payment of $3 million from ViroPharma to Halozyme. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell</title>
		<link>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032</link>
		<comments>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:49:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83032</guid>
		<description><![CDATA[We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal cancer (mCRC). Enzon decided to halt development as the company intends to focus its resources on other areas with nearer-term commercial potential. The discontinuation of development of PEG-SN38 for mCRC is a disappointment, leaving the company with just one clinical program in mid-stage development (PEG-SN38 for metastatic breast cancer) and all others in early stages of development. The company’s pipeline candidates include PEG-SN38, hypoxia-inducible factor1 (HIF-1) alpha, survivin antagonists and multiple messenger RNA (mRNA) antagonists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/14/dndn-dendreon-analyst-maintains-neutral-on-shares/82376</link>
		<comments>http://www.stockbloghub.com/2011/09/14/dndn-dendreon-analyst-maintains-neutral-on-shares/82376#comments</comments>
		<pubDate>Wed, 14 Sep 2011 16:42:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82376</guid>
		<description><![CDATA[We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results. Dendreon Corporation reported weaker-than-expected second quarter 2011 sales of $49.6 million of its potential blockbuster prostate cancer vaccine Provenge, though up from prior quarters. Revenues also disappointed the Zacks Consensus Estimate of $59 million in the second quarter. Management surmised that though the physician interest in the vaccine remains solid, its uptake will be slow and gradual. Subsequently, the company withdrew its revenue guidance for the drug, sending its share price down sharply. Provenge is the first product in a new therapeutic class known as &#8220;active cellular immunotherapies.&#8221; We believe that Provenge is capable of changing the paradigm of cancer care dramatically. Provenge is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/14/dndn-dendreon-analyst-maintains-neutral-on-shares/82376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACHN) Company News for September 9, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/09/09/achn-company-news-for-september-9-2011-corporate-summary/82883</link>
		<comments>http://www.stockbloghub.com/2011/09/09/achn-company-news-for-september-9-2011-corporate-summary/82883#comments</comments>
		<pubDate>Fri, 09 Sep 2011 17:31:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Achillion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ACHN]]></category>
		<category><![CDATA[Caliper Life Sciences Inc]]></category>
		<category><![CDATA[CALP]]></category>
		<category><![CDATA[Casey's General Stores Inc.]]></category>
		<category><![CDATA[CASY]]></category>
		<category><![CDATA[G-III Apparel Group Limited]]></category>
		<category><![CDATA[GIII]]></category>
		<category><![CDATA[GKK]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Gramercy Capital Corporation]]></category>
		<category><![CDATA[PerkinElmer Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKI]]></category>
		<category><![CDATA[SFD]]></category>
		<category><![CDATA[SILC]]></category>
		<category><![CDATA[Silicom Limited]]></category>
		<category><![CDATA[Smithfield Foods Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82883</guid>
		<description><![CDATA[•    Smithfield Foods (NYSE:SFD) posted Q1 EPS of $0.69, surpassing the Zacks Consensus Estimate of $0.68 per share. Revenues for the quarter rose 6.6% year-over-year to $3.09 billion •    PerkinElmer, Inc. (NYSE:PKI) said it will acquire Caliper Life Sciences Inc. (NASDAQ:CALP) in a deal worth about $600 million. Following this development, shares of the genomic-detection tech maker advanced 41.14% to close at $10.43 •    Shares of retailer Casey’s General Stores, Inc. (NASDAQ:CASY) declined 6.54% after the company reported first-quarter earnings results that came in below the Street’s expectations •    Zagat, which provides reviews of bars, restaurants and shopping locations, will be acquired by Google (NASDAQ:GOOG). However, Google remained silent on the terms and conditions of the deal •    Clothing and luggage maker G-III Apparel Group, Ltd.’s (NASDAQ:GIII) share prices fell ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/09/achn-company-news-for-september-9-2011-corporate-summary/82883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747</link>
		<comments>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81747</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for Human Genome. The subsequent approvals of the drug in the European Union (EU) and Canada are also encouraging. The drug, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Lupus is a potentially fatal autoimmune disease that is extremely difficult to treat. We believe that the approval of this potentially blockbuster candidate will drive Human Genome to profitability. Benlysta ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ONXX) Onyx Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354</link>
		<comments>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81354</guid>
		<description><![CDATA[We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved sales of the company’s only marketed drug, Nexavar (sorafenib) for cancer, which came in at $245.7 million (up 4% year-over-year) during the quarter, Onyx Pharma’s revenues experienced a 1.2% decline, amounting to $68.0 million. Earnings were further reduced as a result of higher-than-expected operating expenses. While research and development (R&#38;D) spend went up 16.2% to $50.3 million, selling, general and administrative (SG&#38;A) expenses shot up 43.6% to $38.2 million. Increased expenses for the development of carfilzomib led to higher R&#38;D spend and an increase in employee headcount and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/08/15/optr-optimer-pharmaceuticals-bull-of-the-day/81296</link>
		<comments>http://www.stockbloghub.com/2011/08/15/optr-optimer-pharmaceuticals-bull-of-the-day/81296#comments</comments>
		<pubDate>Mon, 15 Aug 2011 13:56:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81296</guid>
		<description><![CDATA[Optimer Pharmaceuticals&#8217; (OPTR) second quarter 2011 loss per share of $0.52 was wider than the year-ago loss, but we are encouraged by the FDA approval and subsequent launch of Dificid, an antibiotic which treats a condition known as CDAD. Dificid scores better than currently available treatment options on many parameters. Particularly, we believe the inclusion of superior recurrence benefits over Vancocin in the product label will provide valuable benefit and help Dificid sales. Further, the deals with Cubist and Astellas are positive for Optimer as it will benefit from their experience in marketing hospital-based antibiotics. Thus, we have an Outperform recommendation on Optimer with a target price of $9.00. Optimer also currently carries a Zacks #1 Rank (Strong Buy). OPTIMER PHARMAC (OPTR): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/15/optr-optimer-pharmaceuticals-bull-of-the-day/81296/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANX) Company News for August 11, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/11/anx-company-news-for-august-11-2011-corporate-summary/81137</link>
		<comments>http://www.stockbloghub.com/2011/08/11/anx-company-news-for-august-11-2011-corporate-summary/81137#comments</comments>
		<pubDate>Thu, 11 Aug 2011 19:37:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Adventrx Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANX]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[Polo Ralph Lauren Corporation]]></category>
		<category><![CDATA[RL]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[Toreador Resources Corporation]]></category>
		<category><![CDATA[TRGL]]></category>
		<category><![CDATA[Walt Disney Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81137</guid>
		<description><![CDATA[•    According to a report in The New York Times, Capital One (NYSE:COF) has decided to acquire the U.S. credit card business segment of HSBC holdings (NYSE:HSBC)  in a deal estimated to be over $2 billion •    MakeMyTrip Limited (NASDAQ:MMYT) posted Q1 EPS of $0.04, surpassing analysts’ consensus estimate of $0.03 per share. Revenues for the quarter rose 51.8% year-over-year to $21.1 million •    ZaZa Energy and Toreador Resources Corporation (NASDAQ:TRGL) said they have signed a definitive agreement to merge the two companies •    Share prices of The Bank of New York Mellon Corp. (NYSE:BK) declined 7.82% after the banking company announced it would axe 1,500 jobs to cut costs •    Shares of pharma company ADVENTRX Pharmaceuticals Inc (AMEX:ANX) fell 58.27% to close at $1.06 after the company on Tuesday ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/11/anx-company-news-for-august-11-2011-corporate-summary/81137/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals&#8217; Weak Top Line Widens Loss</title>
		<link>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950</link>
		<comments>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:23:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80950</guid>
		<description><![CDATA[Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty revenue neutralized the savings from cost-cutting initiatives. The Zacks Consensus Estimate indicated a break-even for the company. Total revenue at Enzon was $9.6 million, sharply down 30% year over year due to the decline in royalty revenue. Revenue was also much below the Zacks Consensus Estimate of $15 million. Royalty revenue in the quarter dropped around 13% to $9.2 million. Enzon earns the majority of its royalty revenue from the sale of PegIntron, marketed by Merck &#38; Co. (MRK), for treating patients suffering from hepatitis C virus (HCV). The decline in royalty revenue in the reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gains &#8211; Earnings Miss Estimates</title>
		<link>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628</link>
		<comments>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:47:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80628</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s earnings. Revenues Quarterly revenues shot up 52.4% to $65.3 million, driven primarily by strong Ampyra sales. However, revenues marginally missed the Zacks Consensus Estimate of $67 million. Second quarter revenues comprised $62.9 million (up 55.3%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $51.8 million, reflecting a year-over-year increase of 85%. Ampyra, aimed at improving walking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Earnings Grow With HIV Franchise</title>
		<link>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025</link>
		<comments>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:46:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80025</guid>
		<description><![CDATA[Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid top-line performance in the reported quarter. Earnings were however a penny short of the Zacks Consensus Estimate. Second quarter revenues were up 11% from the prior-year quarter to $2.14 billion. Total revenues also topped the Zacks Consensus Estimate of $2.10 billion. Revenue performance was driven by a robust performance of the antiviral (HIV) and cardiovascular franchises. The Second Quarter in Detail Product sales, at $2.04 billion, were up 13% over the prior year due to a strong performance of antiviral products. Gilead’s product sales crossed the $2 billion mark for the first time in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Quarterly Earnings Lag &#8211; Company Pares Loss</title>
		<link>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335</link>
		<comments>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:45:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80335</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower loss per share in the reported quarter was due to lower operating expenses and lower deemed dividend paid to preferred shareholders. The Zacks Consensus Estimate for the reported quarter was a loss of 12 cents per share. Cell Therapeutics did not generate any revenue during the reported quarter versus $0.029 million in the second quarter of 2010. Total operating expense in the quarter declined 15% to $16.9 million. Pipeline Update In June this year, Cell Therapeutics met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

